New Product Penetration:
Understanding & Accelerating
New Product Uptake
"Action is power"
This advice is increasingly relevant for pharmaceutical companies when it comes to shaping the uptake curve of new products in today's evolving markets.
With rapidly changing market factors, new opinion leader groups and the importance of a product's clinical-economic benefits, finding effective ways to keep pace with these changes is critical. However, many pharma companies are not aware of this, and remain complacent about taking appropriate action.
In New Product Penetration: Understanding & Accelerating New Product Uptake, FirstWord Dossier reviews the differences between complex pharmaceutical adoption curves versus simple textbook bell curves. It identifies the latest key drivers and barriers to new product penetration. The report also examines strategic tactics that big pharma are now using to improve their uptake curves.
Report Overview
New Product Penetration: Understanding & Accelerating New Product Uptake summarises the key issues around this important subject. It includes exclusive feedback from in-depth interviews with experienced directors from leading pharmaceutical companies. The report discusses examples of pre and peri-launch tactics companies are using to improve product adoption. It also outlines key questions that you should consider when looking to increase your new product uptake.
Key Report Features
- Views from global marketing directors of leading pharma companies
- Various tactics to help develop and deliver rapid product uptake
- The need for combined clinical and economic product benefits
- The importance of segmenting the market at a clinical, payer and patient level
- Structural company changes to improve new product penetration
- The role of non-traditional KOL groups in securing market access
- Coordination of cross-functional and geographic launch activities
- Actions that big pharma companies are taking to improve product uptake
Who Would Benefit From This Report?
This report will be of value to pharma directors and managers with responsibilities in the following areas:
- Market access
- Marketing
- Business development
- Brand marketing
- Sales management
- Pharmacoeconomics
- Clinical research development
- Corporate communications
- Key Opinion Leader liaison
- Patient Advocacy liaison
- Medical affairs
Key Quotes
“Stalled or uneven product uptake is a classic sign of a lack of strategic segmentation,”
– Bhupendra Patel, executive director, global marketing, Johnson & Johnson.
“The way we launched in the past, with a good premarketing campaign and a major launch strategy, doesn’t works very well now because payers and governments have put up so many barriers in getting access to the market,”
– Stephen Lewington, senior director global marketing & medical affairs, Almirall.
“The old, functional way of working created internal barriers to resource allocation. It prevented us from looking at the bigger picture. But the new market-based company structure has been a huge way for us to really accelerate market uptake,”
– Uday Bose, European head of oncology, Eisai.
“Market access strategy can make a lot of difference to speeding up adoption. It's no longer enough, of course, for a product to be approved; somebody needs to pay for it,”
– Ashwin Dandekar, senior vice president, Campbell Associates.
“Key opinion leaders were once synonymous with clinical professionals but this is now a much broader category. The KOLs of the patient advocacy groups have become very influential, and they will be directed by products to help their constituency,”
– Ian Talmage, senior vice president, global marketing, Bayer.
